文献速递类风湿关节炎

抗肽酰精氨酸脱亚胺酶4抗体中的重链恒定区使用作为类风湿关节炎疾病亚群的标志物

Heavy Chain Constant Region Usage in Antibodies to Peptidylarginine Deiminase 4 as a Marker of Disease Subsets in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2022-09-29

在196例类风湿关节炎(RA)患者和64例健康对照中检测抗PAD4抗体各同种型及IgG亚类,发现抗PAD4 IgG1、IgG3和IgE与不同临床特征相关,IgG1可预测影像学关节损伤进展,IgE与更高疾病活动度、类风湿结节和间质性肺病相关。

要点

  • 抗PAD4 IgG1与影像学关节损伤进展相关(OR 4.88,P=0.005),在基线无关节损伤者中40% versus 0%。
  • 抗PAD4 IgG3患者基线关节损伤评分更高(中位Sharp/van der Heijde评分13 versus 7,P=0.046)。
  • 抗PAD4 IgE患者DAS28更高(中位4.0 versus 3.5),类风湿结节和间质性肺病更常见。

核心结论

  • 抗PAD4 IgG1、IgG3和IgE抗体识别RA中不同的疾病亚群,提示重链使用驱动抗PAD4抗体在RA中的不同效应机制。

研究设计与样本

  • 在196例RA患者和64例健康对照中,用酶联免疫吸附试验测定抗PAD4抗体类型,分析其与临床结局的关联,并在一个独立的RA队列中验证相关特征。

主要发现

  • 抗PAD4 IgG1、IgG2、IgG3、IgG4、IgA和IgE抗体在RA患者中较健康对照更常见(P < 0.001)。
  • 抗PAD4 IgG1预测影像学关节损伤进展(OR 4.88,P = 0.005),尤其在基线无关节损伤的RA患者中(40% versus 0%,P = 0.003)或抗环瓜氨酸肽和/或类风湿因子阴性的患者中(OR 32;P = 0.009)。
  • 抗PAD4 IgG1还与更高水平的C反应蛋白(P = 0.006)和白细胞介素-6(P = 0.021)相关。
  • 抗PAD4 IgG3的RA患者基线关节损伤评分更高(中位Sharp/van der Heijde评分13 versus 7,P = 0.046)。
  • 抗PAD4 IgE的RA患者28关节疾病活动度评分更高(中位4.0 versus 3.5,P = 0.025),类风湿结节更常见(31% versus 16%,P = 0.025),间质性肺病(磨玻璃影)更常见(24% versus 9%,P = 0.014)。

关键数值与推荐

  • 抗PAD4 IgG1预测影像学关节损伤进展:OR 4.88,P = 0.005。
  • 基线无关节损伤的RA患者中,抗PAD4 IgG1阳性者关节损伤进展比例40% versus 阴性者0%(P = 0.003)。
  • 抗环瓜氨酸肽和/或类风湿因子阴性的RA患者中,抗PAD4 IgG1与关节损伤进展的OR 32(P = 0.009)。
  • 抗PAD4 IgG3阳性 versus 阴性RA患者基线中位Sharp/van der Heijde评分13 versus 7(P = 0.046)。
  • 抗PAD4 IgE阳性 versus 阴性RA患者中位DAS28 4.0 versus 3.5(P = 0.025),类风湿结节31% versus 16%(P = 0.025),间质性肺病(磨玻璃影)24% versus 9%(P = 0.014)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study of autoantibody isotypes in autoimmune diseases is useful for identifying clinically relevant endotypes. This study was undertaken to study the prevalence and clinical significance of different isotypes and IgG subclasses of anti-peptidylarginine deiminase 4 (anti-PAD4) autoantibodies in individuals with rheumatoid arthritis (RA). METHODS: In 196 RA subjects and 64 healthy controls, anti-PAD4 antibody types were determined using enzyme-linked immunosorbent assay. We investigated associations between anti-PAD4 antibodies and clinical outcomes, and relevant features were confirmed in an independent RA cohort. RESULTS: Anti-PAD4 IgG1, anti-PAD4 IgG2, anti-PAD4 IgG3, anti-PAD4 IgG4, anti-PAD4 IgA, and anti-PAD4 IgE antibodies were more frequent in RA patients than healthy controls (P < 0.001). Anti-PAD4 IgG1, anti-PAD4 IgG3, and anti-PAD4 IgE were associated with distinct clinical features. Anti-PAD4 IgG1 was predictive of progressive radiographic joint damage (odds ratio [OR] 4.88, P = 0.005), especially in RA patients without baseline joint damage (40% versus 0%, P = 0.003) or in those negative for anti-cyclic citrullinated peptide and/or rheumatoid factor (OR 32; P = 0.009). IgG1 was also associated with higher levels of C-reactive protein (P = 0.006) and interleukin-6 (P = 0.021). RA patients with anti-PAD4 IgG3 had higher baseline joint damage scores (median Sharp/van der Heijde score 13 versus 7, P = 0.046), while those with anti-PAD4 IgE had higher Disease Activity Score in 28 joints (median 4.0 versus 3.5, P = 0.025), more frequent rheumatoid nodules (31% versus 16%, P = 0.025), and more frequent interstitial lung disease (ground-glass opacification) (24% versus 9%, P = 0.014). Anti-PAD4 IgG1 antibody associations with joint damage were corroborated in an independent RA cohort. CONCLUSION: Anti-PAD4 IgG1, anti-PAD4 IgG3, and anti-PAD4 IgE antibodies identify discrete disease subsets in RA, suggesting that heavy chain usage drives distinct effector mechanisms of anti-PAD4 antibodies in RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Gómez-Bañuelos E, Shi J, Wang H, et al. Heavy Chain Constant Region Usage in Antibodies to Peptidylarginine Deiminase 4 as a Marker of Disease Subsets in Rheumatoid Arthritis. Arthritis Rheumatol. 2022. PMID: 35675168. doi:10.1002/art.42262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。